Trial Profile
Retrospective study for Lenvatinib for unresectable thyroid cancers.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 25 Jan 2018 New trial record